FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2030386219> ?p ?o ?g. }

• W2030386219 endingPage "5" @default.
• W2030386219 startingPage "1" @default.
• W2030386219 abstract "Thyroid cancer is a common endocrine-related cancer with a higher incidence in women than in men. Thyroid tumors are classified on the basis of their histopathology as papillary, follicular, medullary, and undifferentiated or anaplastic. Epidemiological and in vitro or in vivo studies have suggested a correlation between incidence of thyroid malignancies and hormones. In particular, growing evidence indicates a role of estrogens and estrogen receptors (ERs) in thyroid tumorigenesis, reprogramming and progression. In this scenario, estrogens are hypothesized to contribute to the observed female predominance of thyroid cancer in reproductive years. However, the precise contribution of estrogens in thyroid proliferative disease initiation and progression is not well understood. HIF-1α and NF-κB are two transcription factors very frequently activated in tumors and involved in tumor growth, progression and resistance to chemotherapy. In fact, HIF-1α and NF-κB together regulate transcription of over a thousand genes that, in turn, control vital cellular processes such as adaptation to the hypoxia, metabolic and differentiation reprogramming, inflammatory-reparative response, extracellular matrix digestion, migration and invasion, adhesion, etc. Because of this wide involvement, they could control in an integrated manner the origin of the malignant phenotype. Interestingly, hypoxia and inflammation have been sequentially bridged in tumors by the discovery that alarmin receptors genes such as RAGE, P2X7 and some TLRs are activated by HIF-1α; and that, in turn, alarmin receptors strongly activate NF-κB and proinflammatory gene expression, evidencing all the hallmarks of the malignant phenotype. Recently, a large number of drugs have been identified that inhibit one or both transcription factors with promising results in terms of controlling tumor progression. In addition, many of these inhibitors are natural compounds or off-label drugs already used to cure other pathologies. Some of them are undergoing clinical trials and soon they will be used alone or in combination with standard anti-tumoral agents to achieve a better treatment of tumors to achieve a reduction of metastasis formation and, more importantly, a net increase in survival. This review highlights the central role of HIF-1α activated in hypoxic regions of the tumor, of NF-κB activation and proinflammatory gene expression in transformed thyroid cells to understand their progression toward malignancy. The role of ER-α will be underlined, considering also its role in reprogramming cancer cells." @default.
• W2030386219 created "2016-06-24" @default.
• W2030386219 creator A5043740687 @default.
• W2030386219 creator A5054485016 @default.
• W2030386219 creator A5054487693 @default.
• W2030386219 creator A5056025765 @default.
• W2030386219 creator A5058072473 @default.
• W2030386219 creator A5062026629 @default.
• W2030386219 creator A5064406981 @default.
• W2030386219 creator A5081012227 @default.
• W2030386219 creator A5086445525 @default.
• W2030386219 creator A5086844490 @default.
• W2030386219 date "2014-02-01" @default.
• W2030386219 modified "2023-10-17" @default.
• W2030386219 title "Bridging hypoxia, inflammation and estrogen receptors in thyroid cancer progression" @default.
• W2030386219 cites W1964033749 @default.
• W2030386219 cites W1970744454 @default.
• W2030386219 cites W1973137179 @default.
• W2030386219 cites W1975916185 @default.
• W2030386219 cites W1976052099 @default.
• W2030386219 cites W1981467972 @default.
• W2030386219 cites W1986731085 @default.
• W2030386219 cites W2001644486 @default.
• W2030386219 cites W2008202172 @default.
• W2030386219 cites W2009925064 @default.
• W2030386219 cites W2028368780 @default.
• W2030386219 cites W2028897202 @default.
• W2030386219 cites W2032356402 @default.
• W2030386219 cites W2039753813 @default.
• W2030386219 cites W2048686120 @default.
• W2030386219 cites W2052926310 @default.
• W2030386219 cites W2066651426 @default.
• W2030386219 cites W2071333584 @default.
• W2030386219 cites W2072879909 @default.
• W2030386219 cites W2074089133 @default.
• W2030386219 cites W2076612253 @default.
• W2030386219 cites W2076743940 @default.
• W2030386219 cites W2079943798 @default.
• W2030386219 cites W2102589798 @default.
• W2030386219 cites W2102943268 @default.
• W2030386219 cites W2107094925 @default.
• W2030386219 cites W2107278092 @default.
• W2030386219 cites W2117692326 @default.
• W2030386219 cites W2118278569 @default.
• W2030386219 cites W2118655588 @default.
• W2030386219 cites W2121454015 @default.
• W2030386219 cites W2123105952 @default.
• W2030386219 cites W2125153669 @default.
• W2030386219 cites W2125987139 @default.
• W2030386219 cites W2130875721 @default.
• W2030386219 cites W2137681063 @default.
• W2030386219 cites W2144248079 @default.
• W2030386219 cites W2146778631 @default.
• W2030386219 cites W2149411458 @default.
• W2030386219 cites W2150611307 @default.
• W2030386219 cites W2155018872 @default.
• W2030386219 cites W2156945586 @default.
• W2030386219 cites W2167281518 @default.
• W2030386219 cites W2169675346 @default.
• W2030386219 cites W2170798389 @default.
• W2030386219 cites W2216094174 @default.
• W2030386219 cites W2315613727 @default.
• W2030386219 cites W4231356616 @default.
• W2030386219 doi "https://doi.org/10.1016/j.biopha.2013.10.013" @default.
• W2030386219 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24286852" @default.
• W2030386219 hasPublicationYear "2014" @default.
• W2030386219 type Work @default.
• W2030386219 sameAs 2030386219 @default.
• W2030386219 citedByCount "41" @default.
• W2030386219 countsByYear W20303862192014 @default.
• W2030386219 countsByYear W20303862192015 @default.
• W2030386219 countsByYear W20303862192016 @default.
• W2030386219 countsByYear W20303862192017 @default.
• W2030386219 countsByYear W20303862192018 @default.
• W2030386219 countsByYear W20303862192019 @default.
• W2030386219 countsByYear W20303862192020 @default.
• W2030386219 countsByYear W20303862192021 @default.
• W2030386219 countsByYear W20303862192022 @default.
• W2030386219 countsByYear W20303862192023 @default.
• W2030386219 crossrefType "journal-article" @default.
• W2030386219 hasAuthorship W2030386219A5043740687 @default.
• W2030386219 hasAuthorship W2030386219A5054485016 @default.
• W2030386219 hasAuthorship W2030386219A5054487693 @default.
• W2030386219 hasAuthorship W2030386219A5056025765 @default.
• W2030386219 hasAuthorship W2030386219A5058072473 @default.
• W2030386219 hasAuthorship W2030386219A5062026629 @default.
• W2030386219 hasAuthorship W2030386219A5064406981 @default.
• W2030386219 hasAuthorship W2030386219A5081012227 @default.
• W2030386219 hasAuthorship W2030386219A5086445525 @default.
• W2030386219 hasAuthorship W2030386219A5086844490 @default.
• W2030386219 hasConcept C121608353 @default.
• W2030386219 hasConcept C126322002 @default.
• W2030386219 hasConcept C134018914 @default.
• W2030386219 hasConcept C2779256057 @default.
• W2030386219 hasConcept C2779761222 @default.
• W2030386219 hasConcept C2780120053 @default.
• W2030386219 hasConcept C502942594 @default.
• W2030386219 hasConcept C526584372 @default.

• next